(NASDAQ: BIVI) Biovie's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.76%.
Biovie's earnings in 2026 is -$22,590,376.On average, 3 Wall Street analysts forecast BIVI's earnings for 2027 to be -$6,891,708, with the lowest BIVI earnings forecast at -$6,621,445, and the highest BIVI earnings forecast at -$7,094,405. On average, 3 Wall Street analysts forecast BIVI's earnings for 2028 to be -$6,235,355, with the lowest BIVI earnings forecast at -$5,990,831, and the highest BIVI earnings forecast at -$6,418,747.
In 2029, BIVI is forecast to generate -$6,016,570 in earnings, with the lowest earnings forecast at -$5,780,626 and the highest earnings forecast at -$6,193,528.